| Pharmacogenetics of plasma efavirenz exposure in HIV‐infected adults and children in South Africa PZ Sinxadi, PD Leger, HM McIlleron, PJ Smith, JA Dave, NS Levitt, ... British journal of clinical pharmacology 80 (1), 146-156, 2015 | 86 | 2015 |
| CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz R Griesel, G Maartens, M Chirehwa, S Sokhela, G Akpomiemie, ... Clinical Infectious Diseases 73 (11), e3902-e3909, 2021 | 78 | 2021 |
| Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype HM McIlleron, M Schomaker, Y Ren, P Sinxadi, JJC Nuttall, H Gous, ... Aids 27 (12), 1933-1940, 2013 | 68 | 2013 |
| Plasma efavirenz concentrations are associated with lipid and glucose concentrations PZ Sinxadi, HM McIlleron, JA Dave, PJ Smith, NS Levitt, DW Haas, ... Medicine 95 (2), e2385, 2016 | 51 | 2016 |
| Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers P Sinxadi, C Donini, H Johnstone, G Langdon, L Wiesner, E Allen, ... Antimicrobial agents and chemotherapy 64 (4), 10.1128/aac. 01896-19, 2020 | 47 | 2020 |
| Warfarin resistance: cardiovascular prescriber P Sinxadi, M Blockman Cardiovascular Journal of Africa 19 (4), 215-217, 2008 | 44 | 2008 |
| Efavirenz pharmacogenetics and weight gain following switch to integrase inhibitor–containing regimens MA Leonard, Z Cindi, Y Bradford, K Bourgi, J Koethe, M Turner, ... Clinical Infectious Diseases 73 (7), e2153-e2163, 2021 | 43 | 2021 |
| A comparison of plasma efavirenz and tenofovir, dried blood spot tenofovir-diphosphate, and self-reported adherence to predict virologic suppression among South African women TK Phillips, P Sinxadi, EJ Abrams, A Zerbe, C Orrell, NC Hu, K Brittain, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 81 (3), 311-318, 2019 | 35 | 2019 |
| Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites EH Decloedt, PZ Sinxadi, GU van Zyl, L Wiesner, S Khoo, JA Joska, ... Journal of Antimicrobial Chemotherapy 74 (3), 699-709, 2019 | 20 | 2019 |
| Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study PZ Sinxadi, JA Dave, DC Samuels, JM Heckmann, G Maartens, NS Levitt, ... AIDS Research and Human Retroviruses 29 (7), 1031-1039, 2013 | 20 | 2013 |
| Understanding the implications of mitochondrial DNA variation in the health of black southern African populations: The 2014 Workshop F Van der Westhuizen, PZ Sinxadi, C Dandara, I Smuts, G Riordan, ... Wiley, 2015 | 19 | 2015 |
| Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): A randomised, open-label … WDF Venter, M Moorhouse, S Sokhela, C Serenata, G Akpomiemie, ... The Lancet HIV 6 (7), e428-e437, 2019 | 17 | 2019 |
| Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome (LENS) R van Rensburg, S Nightingale, N Brey, CH Albertyn, TA Kellermann, ... Clinical Infectious Diseases 75 (3), 399-405, 2022 | 16 | 2022 |
| Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy R Griesel, AN Kawuma, R Wasmann, S Sokhela, G Akpomiemie, ... British journal of clinical pharmacology 88 (3), 883-893, 2022 | 15 | 2022 |
| Pharmacokinetic interactions of modern antiretroviral therapy PZ Sinxadi, SH Khoo, M Boffito AIDS 35 (Supplement 2), S145-S151, 2021 | 10 | 2021 |
| Building capability for clinical pharmacology research in sub‐Saharan Africa MM Gutierrez, G Pillai, S Felix, F Romero, KO Onyango, S Owusu‐Agyei, ... Clinical Pharmacology & Therapeutics 102 (5), 786-795, 2017 | 9 | 2017 |
| Genetic associations with weight gain among South Africans who initiated dolutegravir-containing and tenofovir-containing regimens Z Cindi, G Maartens, Y Bradford, WDF Venter, S Sokhela, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 87 (3), 1002-1009, 2021 | 7 | 2021 |
| Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study PZ Sinxadi, JS van der Walt, HM McIlleron, M Badri, PJ Smith, JA Dave, ... AIDS Research and Therapy 7, 1-6, 2010 | 7 | 2010 |
| Pharmacology of anthelmintics: Albendazole, Mebendazole and praziquantel G Maartens, P Sinxadi CME 27, 2009 | 7 | 2009 |
| Pharmacogenetics of dolutegravir plasma exposure among southern Africans with human immunodeficiency virus Z Cindi, AN Kawuma, G Maartens, Y Bradford, F Venter, S Sokhela, ... The Journal of infectious diseases 226 (9), 1616-1625, 2022 | 5 | 2022 |
Naomi Sharlene Levitt在 uct.ac.za 的电子邮件经过验证
